Company: TAK
Filing Date: 2025-06-26
Form Type: 424B5
Source: 0001395064-25-000101
Chunk: 6

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-26
Form: 424B5
Chunk 6
---
 Takeda’s most recent annual report on Form 20-F and in the “Risk Factors” section of this prospectus supplement. Other factors could also adversely affect Takeda’s results or the accuracy of forward-looking statements in this prospectus supplement, the accompanying prospectus or the documents incorporated by reference herein and therein, and you should not consider these to be a complete set of all potential risks or uncertainties.

The forward-looking statements included or incorporated by reference in this prospectus supplement and the accompanying prospectus are made only as of the dates on which such statements were made. The Issuer, the Guarantor and Takeda expressly disclaim any obligation or undertaking to release any update or revision to any forward-looking statement contained herein or therein to reflect any change in their expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.

<div align='center'>S-iv</div>

### PRESENTATION OF FINANCIAL AND OTHER INFORMATION
In this prospectus supplement, the term “Takeda” refers to Takeda Pharmaceutical Company Limited and, unless the context requires otherwise, its consolidated subsidiaries including TUSFI. The terms “TPC” and the “Guarantor” refers to Takeda Pharmaceutical Company Limited on a standalone basis as the guarantor of the Notes. The terms “TUSFI” and the “Issuer” refer to Takeda U.S. Financing, Inc. as the issuer of the Notes. The terms “we,” “us” and “our” refer to TPC (as the context requires, on a consolidated or standalone basis) and TUSFI collectively. We use the word “you” to refer to prospective investors in the Notes and the word “holder,” “Noteholder” or “Noteholders” to refer to the holders of the Notes.

Takeda’s consolidated financial statements are prepared on an annual and quarterly basis in accordance with the International Financial Reporting Standards as issued by the International Accounting Standards Board (“IFRS”). The term IFRS also includes International Accounting Standards (“IAS”) and the related interpretations of the committees (Standard Interpretations Committee and International Financial Reporting Interpretations Committee). Unless otherwise stated or otherwise required by the context, all amounts in our financial statements are denominated in yen, the legal tender of Japan. Unless otherwise specified, Takeda’s financial information contained or incorporated by reference herein or in the accompanying prospectus is presented in accordance with IFRS, as specified herein or in the relevant document being incorporated by